title: Microbial contamination of hematopoietic progenitor cell products: clinical outcome.
abstract: We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infusions received empirical antibiotic prophylaxis according to the assay result. None of these patients developed a positive blood culture with the same agent, developed infections that could be attributable to the contaminated product or experienced any clinical sequelae. Coagulase-negative Staphylococcus was found in 32 (86.5%) products. Admission lengths and time to engraftment were within the expected time frame for autologous and allogeneic transplants. Microbial contamination of HPC products occurs at a low frequency; prophylactic use of antibiotics based on the microbiological assay appears to be effective in preventing clinical complications.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77035, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Patah
authors.forename: S
authors.initials: S
authors.lastname: Parmar
authors.forename: J
authors.initials: J
authors.lastname: McMannis
authors.forename: T
authors.initials: T
authors.lastname: Sadeghi
authors.forename: S
authors.initials: S
authors.lastname: Karandish
authors.forename: G
authors.initials: G
authors.lastname: Rondon
authors.forename: J
authors.initials: J
authors.lastname: Tarrand
authors.forename: R
authors.initials: R
authors.lastname: Champlin
authors.forename: M
authors.initials: M
authors.lastname: de Lima
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
mesh_terms: D019072:Antibiotic Prophylaxis / Q000379:methods; D016470:Bacteremia / Q000517:prevention & control; D001781:Blood Component Removal / Q000379:methods; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells / Q000382:microbiology*; D006801:Humans; D008485:Medical Audit; D012189:Retrospective Studies; D013781:Texas; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous